Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.05
Bid: 3.80
Ask: 4.30
Change: 0.15 (3.85%)
Spread: 0.50 (13.158%)
Open: 3.90
High: 4.05
Low: 3.72
Prev. Close: 3.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

27 Jun 2019 07:00

RNS Number : 5736D
Allergy Therapeutics PLC
27 June 2019
 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Trading Update and Successful Litigation Settlement

 

2019 full year earnings expected to be ahead of market expectations

 

 

27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II trial. The Group will announce its post year-end trading update on 11 July 2019 and preliminary results on 25 September 2019.

 

Net sales this year are likely to be in line with market expectations showing good growth over the past year on a constant currency basis across most of Europe but especially in Spain, Netherlands and Switzerland. In terms of products, Venomil, Pollinex and Pollinex Quattro have all performed well and Acarovac Plus continues to be a top performing product in Spain.

 

As a result of lower than anticipated overheads through cost control and lower R&D costs (now expected to be less than £14m), due to the timing of the Grass MATA MPL Phase III trial, the Group now expects earnings for the full year 2019 to be ahead of market expectations.

 

As announced separately today, the Group has also received a $7.6m settlement from Inflamax Research Inc. ("Inflamax") in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16. Inflamax has also agreed to pay a substantial part of the Group's legal costs.

 

Commenting on announcement, Manuel Llobet, CEO of Allergy Therapeutics, said: "Allergy Therapeutics has continued to perform strongly this year, combining good sales performance with strong cost control, resulting in earnings ahead of market expectations for the full year. With the announcement today of a successful litigation result in relation to the Grass MATA MPL Phase II trial in challenge chambers, our cash position has been further boosted. We look forward to giving more detail on the Group's performance at our full year results in September."

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

allergytherapeutics@consilium-comms.com

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

 

 

 

 

Notes for editors:

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDMGZVMVLGLZZ
Date   Source Headline
29th Sep 200810:46 amRNSHolding(s) in Company
22nd Sep 20087:00 amRNSFinal Results
22nd Sep 20087:00 amRNSResearch Update
22nd Aug 20083:06 pmRNSHolding(s) in Company
9th Jun 20087:00 amRNSResearch Update
14th May 20087:00 amRNSResearch Update
7th May 200811:50 amRNSDirector/PDMR Shareholding
15th Apr 20082:28 pmRNSAIM Notice 26
17th Mar 20087:01 amRNSInterim Results
14th Mar 200811:59 amRNSHolding(s) in Company
7th Mar 20081:47 pmRNSHolding(s) in Company
31st Jan 20087:00 amRNSNotice of Results
29th Jan 20084:15 pmRNSHolding(s) in Company - Amend
29th Jan 200812:42 pmRNSHolding(s) in Company
14th Jan 20087:01 amRNSChange of Adviser
27th Dec 200710:21 amRNSGrant of Options
12th Dec 200710:28 amRNSAvailability of Annual Report
29th Nov 20072:22 pmRNSResult of AGM
16th Nov 20073:31 pmRNSDirector/PDMR Shareholding
9th Nov 20073:24 pmRNSHolding(s) in Company
1st Nov 20077:02 amRNSResearch Update
29th Oct 20073:39 pmRNSHolding(s) in Company
26th Oct 20073:10 pmRNSDirector/PDMR Shareholding
11th Oct 200710:33 amRNSHolding(s) in Company
25th Sep 20077:00 amRNSFinal Results
14th Aug 20078:00 amRNSChange of Adviser
10th Aug 20079:28 amRNSAIM Rule 26
6th Aug 200711:03 amRNSHolding(s) in Company
24th Jul 200710:41 amRNSResearch Update
17th Jul 20073:36 pmRNSHolding(s) in Company
11th Jul 200710:01 amRNSClinical Update
19th Jun 200711:03 amRNSHolding(s) in Company
14th Jun 20077:01 amRNSResearch Update
8th Jun 20076:00 pmRNSAppointment of Joint Broker
29th May 20079:15 amRNSEur40 million Debt Facility
29th May 20077:02 amRNSEUR40 million Debt Facility
8th May 200710:45 amRNSHolding(s) in Company
18th Apr 20077:01 amRNSResearch Update
2nd Apr 20077:02 amRNSResearch Update
23rd Mar 200711:42 amRNSHolding(s) in Company
23rd Mar 20077:01 amRNSRe Investment
5th Mar 200712:04 pmRNSHolding(s) in Company
28th Feb 20077:01 amRNSInterim Results
27th Feb 200710:21 amRNSHolding(s) in Company
15th Feb 20072:29 pmRNSHolding(s) in Company
6th Feb 20074:46 pmRNSHolding(s) in Company
5th Feb 20073:04 pmRNSHolding(s) in Company
31st Jan 200710:18 amRNSTotal Voting Rights
31st Jan 20077:01 amRNSResearch Update
26th Jan 200710:00 amRNSOpening of Facilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.